Trial Profile
ABSORB BTK Study: A Prospective, Multi-center, Controlled Clinical Evaluation of the Use of a Bioresorbable Drug Eluting Stent (Absorb, Abbott Vascular) in the Arterial Vasculature Below the Knee
Status:
Discontinued
Phase of Trial:
Clinical Phase Unknown
Latest Information Update: 18 Apr 2019
Price :
$35
*
At a glance
- Drugs Everolimus (Primary)
- Indications Arterial occlusive disorders; Chronic limb-threatening ischemia; Peripheral arterial disorders
- Focus Therapeutic Use
- Acronyms ABSORB BTK
- 15 Apr 2019 Status changed from recruiting to discontinued.
- 17 Jun 2016 New trial record